Ensysce Biosciences, Inc. (ENSC) stock

ENSCNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 9/3076% below fair value

$0.42+0.03 (+8.06%)

Close on Nov 13, 2026Market cap $8.14MP/E –Yield –

Ensysce Biosciences ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Ensysce Biosciences has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Ensysce Biosciences's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-15 reverse split on Dec 6, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ENSC.

Revenue growth37.9% · median -44.2%

Operating margin-1477.0% · median -1093.9%

Advertisement
300 × 250

See a number that looks wrong?